Global Information
회사소개 | 문의 | 비교리스트

동반진단 시장 : 미래의 진단 기술 - 맞춤형 예측 및 분석(자금원별, 용도별), 신종 코로나바이러스 감염증(Covid-19)의 영향, 이그제큐티브 및 컨설턴트 가이드(2020-2024년)

Companion Diagnostic Markets - the Future of Diagnostics. by Funding Source and Application with Customized Forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024

리서치사 Howe Sound Research
발행일 2020년 06월 상품 코드 939940
페이지 정보 영문 429 Pages
가격
US $ 6,995 ₩ 8,454,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,684,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,914,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



동반진단 시장 : 미래의 진단 기술 - 맞춤형 예측 및 분석(자금원별, 용도별), 신종 코로나바이러스 감염증(Covid-19)의 영향, 이그제큐티브 및 컨설턴트 가이드(2020-2024년) Companion Diagnostic Markets - the Future of Diagnostics. by Funding Source and Application with Customized Forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024
발행일 : 2020년 06월 페이지 정보 : 영문 429 Pages

동반진단은 진단 업계에 혁명을 일으키고 있습니다. 시장은 마침내 연구실을 나와 임상 현장으로 이동하고 있습니다. 종양, 특히 암면역 종양학이 선도하고 있습니다. 그리고 FDA는 이 미래의 진단 기술에 대한 문을 열고 있습니다. 한편, 신종 코로나바이러스 감염증(Covid-19)의 감염 확대가 의료 시장에 막대한 영향을 미친 결과, 특수 암검사의 수요가 감소하고 있습니다.

동반진단의 향후 기술 진보·시장 성장 전망에 대해 분석했으며, 기술적인 개요 및 주요 활용 분야, 향후 의료 현장에 미치는 영향력, 최근 주요 개발·제품 출시 동향, 주요 기업의 개요와 주력 제품, 향후 시장 규모의 동향 전망, 지역별·용도별·자금원별 상세 동향, 신종 코로나바이러스 감염증(Covid-19) 발생의 영향 등의 정보를 정리하여 전해드립니다.

목차

i. 동반진단 시장 : 전략적 상황 분석

ii. 이그제큐티브·마케팅·판매·비지니스 개발 스탭 대상 제안

iii. 경영 컨설턴트·투자고문 대상 제안

제1장 서론, 시장의 정의

제2장 시장 개요

  • 역동적 시장에서의 참여 기업
    • 교육·연구기관
    • 진단 검사 개발업자
    • 계측 장비 공급업체
    • 시약 유통업체·공급업체
    • 독립계 검사실
    • 국영/공영 검사실
    • 원내 검사실
    • 개업의
    • 감사 기관
    • 인증 기관
  • 맞춤형 의료와 동반진단
    • 기본
    • 방법
    • 질병 리스크 평가
    • 용도
    • 진단과 침습
    • 의약품 개발과 사용
    • 호흡 프로테오믹스
    • 암 게노믹스
    • 집단검진
    • 과제
    • 규제 감독
    • 지적재산권
    • 상환 방침
    • 환자 프라이버시와 기밀성
  • 염색체, 유전자, 에피제네틱스
  • 암유전자
    • 생식 세포와 체세포
    • 임상적 역할의 변화
  • 산업의 구조가 역할을 담당한다.
    • 신규 의약품용 자금 시장
    • 규모의 경제
    • 개업의
    • 의사와 POCT

제3장 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 계측과 자동화
  • 진단 기술 개발
    • 차세대 시퀀싱 : 혁명 촉진
    • 단일세포 게노믹스 : 상황 변혁
    • 약물유전체학 : 진단과 치료의 일체화
    • CGES 검사 : 신세계의 개척
    • 바이오칩/거대 자기저항 기반 어세이

제4장 동반진단 : 최근 진척 상황

  • 이 섹션의 중요성과 활용 방법

제5장 주요 기업의 개요

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid(now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine(now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health(Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

제6장 세계의 동반진단 시장

  • 국가별 분석 : 개요
  • 용도별 분석 : 개요
  • 자금원의 동향/예측 : 개요

제7장 세계의 동반진단 시장 : 용도별

  • 신경증
  • 순환기 질환
  • 기타 용도

제8장 세계의 동반진단 시장 : 자금원별

  • 제약기업
  • 벤처캐피털
  • 임상의료기관
  • 기타

부록

KSA 20.06.19

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 3 Market Players by Type
  • Table 4 The Base Pairs
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 - Global Companion Diagnostic Market by Region
  • Table 10 Global Market by Application
  • Table 11 Global Market by Funding Source
  • Table 12 Oncology by Country
  • Table 13 Neurology by Country
  • Table 14 Cardiology by Country
  • Table 15 Other Application by Country
  • Table 16 Pharmaceutical by Country
  • Table 17 Venture by Country
  • Table 18 Clinical by Country
  • Table 19 Other Funding by Country
  • Table 22 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 4 DNA Strands and Chromosomes
  • Figure 5 Karyogram of Human Chromosomes
  • Figure 6 Size of Various Genomes
  • Figure 7 Germline vs Somatic Mutations
  • Figure 8 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 9 Percentage of World Population Over 65
  • Figure 10 2019 Global Market Density Chart
  • Figure 11 CDx Market by Application - 2019 vs. 2024
  • Figure 12 CDx Market by Application 2019
  • Figure 13 CDx Market by Application 2024
  • Figure 14 Application Type Share by Year
  • Figure 15 Funding Source - 2019 vs. 2024
  • Figure 16 Funding Source Market 2019
  • Figure 17 Funding Source Market 2024
  • Figure 18 Funding Source Share by Year
  • Figure 19 Oncology Growth
  • Figure 20 Neurology Growth
  • Figure 21 Cardiology Growth
  • Figure 22 Other Application Growth
  • Figure 23 Pharmaceutical Growth
  • Figure 24 Venture Growth
  • Figure 25 Clinical Growth
  • Figure 26 Other Funding Growth
  • Figure 27 2020 Clinical Laboratory Fee Schedule

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Companion Diagnostics?
  • 1.2 The Personalized Medicine Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Personalized Medicine and Companion Diagnostics
    • 2.2.1 Basics
    • 2.2.2 Method
    • 2.2.3 Disease risk assessment
    • 2.2.4 Applications
    • 2.2.5 Diagnosis and intervention
      • 2.2.5.1 Companion Diagnostics
    • 2.2.6 Drug development and usage
    • 2.2.7 Respiratory proteomics
    • 2.2.8 Cancer genomics
    • 2.2.9 Population screening
    • 2.2.10 Challenges
    • 2.2.11 Regulatory oversight
    • 2.2.12 Intellectual property rights
    • 2.2.13 Reimbursement policies
    • 2.2.14 Patient privacy and confidentiality
  • 2.3 Chromosomes, Genes and Epigenetics
    • 2.3.1 Chromosomes
    • 2.3.2 Genes
    • 2.3.3 Epigenetics
  • 2.4 Cancer Genes
    • 2.4.1 Germline vs Somatic
    • 2.4.2 Changing Clinical Role
  • 2.5 Structure of Industry Plays a Part
    • 2.5.1 New Pharmaceutical Funding Market
    • 2.5.2 Economies of Scale
      • 2.5.2.1 Hospital vs. Central Lab
    • 2.5.3 Physician Office Labs
    • 2.5.4 Physicians and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Level of Care
    • 3.1.2 Immuno-oncology
    • 3.1.3 Liability
    • 3.1.4 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 State of knowledge
    • 3.2.2 Genetic Blizzard.
    • 3.2.3 Protocol Resistance
    • 3.2.4 Regulation and coverage
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution.
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • FDA Approval for FoundationOne®CDx
      • FDA finalizes CDx Guidance
      • QIAGEN Launches CDx Therascreen BRAF Test
      • Myriad Genetics Seeks Approval for Companion Diagnostic
      • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
      • QIAGEN Builds on Global Collaboration with Amgen
      • Foundation Medicine nabs 19th companion Dx
      • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
      • Myriad Wins Japanese Approval for BRACAnalysis
      • Fujitsu Improves Efficiency in Cancer Genomic Medicine
      • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
      • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
      • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
      • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
      • Universal Genetic Testing for All Breast Cancer Patients
      • Exact Sciences buys Genomic Health
      • Biodesix Highlights Pipeline and Companion Diagnostic Development
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • New Gene Panel Identifies High Risk Prostate Cancer
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for Companion Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Application - Overview
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Global Market by Application - 2019/2024 Comparison
    • 6.2.3 Chart - Global Market by Application - 2019
    • 6.2.4 Chart - Global Market by Application -2024
    • 6.2.5 Chart - Global Market by Application - Share by Year
  • 6.3 Global Market Funding Source - Overview
    • 6.3.1 Table - Global Market by Funding Source
    • 6.3.2 Chart - Global Market Funding Source - 2019/2024 Comparison
    • 6.3.3 Chart - Global Market Funding Source - 2019
    • 6.3.4 Chart - Global Market Funding Source -2024
    • 6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application

  • 7.1 Oncology
    • 7.1.1 Table Oncology - by Country
    • 7.1.2 Chart - Oncology Growth
  • 7.2 Neurology
    • 7.2.1 Table Neurology - by Country
    • 7.2.2 Chart - Neurology Growth
  • 7.3 Cardiology
    • 7.3.1 Table Cardiology - by Country
    • 7.3.2 Chart - Cardiology Growth
  • 7.4 Other Application
    • 7.4.1 Table Other Application - by Country
    • 7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source

  • 8.1 Global Market Pharmaceutical
    • 8.1.1 Table Pharmaceutical - by Country
    • 8.1.2 Chart - Pharmaceutical Growth
  • 8.2 Global Market Venture
    • 8.2.1 Table Venture - by Country
    • 8.2.2 Chart - Venture Growth
  • 8.3 Global Market Clinical
    • 8.3.1 Table Clinical - by Country
    • 8.3.2 Chart - Clinical Growth
  • 8.4 Global Market Other Funding
    • 8.4.1 Table Other Funding - by Country
    • 8.4.2 Chart - Other Funding Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. Pharmacogenomic Biomarkers in Drug Labeling
Back to Top
전화 문의
F A Q